Abu Dhabi medical partners develop non-surgical device for chronic pain and movement disorders
Abu Dhabi’s Sheikh Shakhbout Medical City has partnered with local researchers to develop a non-invasive device for treating chronic pain and movement disorders, according to a press release from the UAE’s Ministry of Health and Prevention. The technology, which uses neurostimulation, is being tested in clinical trials and could offer an alternative to surgery, as reported by Mena FN.
How the device works and its potential impact
The device, described as a “neurostimulation system,” targets specific neural pathways to alleviate chronic pain and manage conditions like Parkinson’s disease, according to a statement from Sheikh Shakhbout Medical City. Unlike traditional surgical interventions, the device operates without incisions, reducing recovery time and risks associated with invasive procedures. A pilot study published in the *Journal of Pain Research* in 2023 found that similar neurostimulation techniques improved mobility in 78% of participants with movement disorders.
Comparison with existing treatments
Chronic pain management typically relies on medication, physical therapy, or surgery. The new device, however, offers a middle ground. “This technology could reduce dependency on opioids, which are often prescribed for chronic pain but carry high addiction risks,” said Dr. Aisha Al Mazrouei, a neurologist at Sheikh Shakhbout Medical City, in a statement. The device’s non-invasive nature contrasts with existing treatments like deep brain stimulation, which requires surgical implantation.
Regulatory and commercial next steps
The UAE’s Ministry of Health and Prevention confirmed that the device is undergoing regulatory review to ensure safety and efficacy. If approved, it could be available in Abu Dhabi’s public healthcare system by 2024, according to a spokesperson. The project aligns with the UAE’s National Innovation Strategy, which prioritizes medical breakthroughs.
Why this matters for global healthcare
Chronic pain affects over 20% of the global population, according to the World Health Organization. Innovations like Abu Dhabi’s device could address gaps in treatment, particularly in regions with limited access to specialized care. “This development reflects a shift toward personalized, technology-driven solutions,” said Dr. Khalid Al Marri, a medical economist at the Abu Dhabi Health Services Company.
Future implications and challenges
While the device shows promise, experts caution that long-term data is needed. “Clinical trials must confirm sustained efficacy and safety over years,” noted a 2023 analysis in *Nature Medicine*. Additionally, scaling production and ensuring affordability could pose challenges. Nonetheless, the project has drawn interest from international health organizations, including the World Health Organization, which is exploring partnerships for global deployment.